- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00483730
Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)
A Multi-centre, Double-blind, Placebo-controlled, Randomised, Parallel Group Clinical Trial to Evaluate Efficacy and Safety of Actovegin® in Diabetic Type 2 Patients With Symptomatic Diabetic Peripheral Polyneuropathy
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Roskilde, Denmark, 4000
- Nycomed
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The medical condition / disease to be studied is symptomatic diabetic peripheral polyneuropathy.
All inclusion criteria must be answered "yes" for a patient to participate in the trial.
- Has the patient given informed consent according to local requirements before any trial related activities? A trial related activity is any procedure that would not have been performed during the routine management of the patient.
- Is the patient aged ≥ 18 to ≤ 65 years?
- Does the patient suffer from type 2 diabetes mellitus?
- Has the patient evidence of symptomatic diabetic peripheral polyneuropathy, i.e. TSS ≥ 6 and NIS-LL ≥ 2?
- Is the patient's VPT measured to ≤ 30V?
- Has the patient adequate circulation to the foot as evidenced by a palpable pulse on posterior tibialis artery and dorsal artery of foot?
- Is the HbA1C level less than 10%?
Is the patient able to make frequent clinic visits over the trial period?
For patients receiving tricyclic antidepressants, anticonvulsants, mexiletine or neuroleptics as treatment of neuropathic pain:
Has the regimen been stable within the last month?
For female patients of childbearing potential (childbearing potential is considered until menopause has lasted more than 12 months):
- Does the patient use an acceptable contraceptive method (hormonal pills, patches, implants, injections or intrauterine device)?
- Is the pregnancy test negative before the 1st dose of trial medication?
(Surgically hysterectomised and surgically successfully sterilized females may be included on the same conditions as male patients).
Exclusion Criteria:
All exclusion criteria must be answered "no" for a patient to participate in the trial.
- Does the patient suffer from known allergy towards Actovegin or similar preparations?
- Has the patient asymmetrical neuropathy of the trunk or proximal lower limbs?
- Does the patient suffer from diabetic foot ulceration or infections?
- Does the patient suffer from diabetic amyotrophy?
- Does the patient suffer from decompensated cardiac insufficiency, pulmonary oedema, oliguria, anuria, generalised oedema?
- Does the patient suffer from polyneuropathy due to other underlying causes?
- Has the patient been hospitalised due to diabetic polyneuropathy within the last month?
- Has the patient participated in any other trial with an Investigational Medicinal Product (IMP) or device within 30 days before inclusion in this trial?
- Has the patient ever used medications that may be etiological factors for neuropathy, such as isoniazid, nitrofurantoin, vincristine and phenytoin?
- Has the patient used cerebrolysin or α-lipoic acid or received Transcutaneous Electric Nerve Stimulation (TENS) or acupuncture within the last month?
- Has the patient received opiates as treatment of his / her diabetic polyneuropathy within the last month?
- Does the patient suffer from any malignancy?
- Is the patient nursing?
- Does the patient suffer from any mental, psychiatric or other conditions that may compromise data collection and understanding of written and verbal information given in the trial?
- Does the patient suffer from present and / or previous chronic alcohol abuse?
- Is there any anamnestic evidence of hypothyroidism?
- Is there any anamnestic evidence of vitamin B12 deficiency?
- Does the patient suffer from an impaired renal function with high blood urea nitrogen (BUN) and / or increased serum creatinine (>120 µmol/L)?
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
TSSaverage: Average of the TSS over the treatment period (AUC / exposure time) VPTaverage: Average of the VPT measurement over the treatment period (AUC / exposure time)
Time Frame: Approx. 5½ months
|
Approx. 5½ months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
NIS-LLaverage: Average of the NIS-LL over the treatment period (AUC / exposure time)
Time Frame: Approx. 5½ months
|
Approx. 5½ months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Nycomced Clinical Trial Operations, Headquaters
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Polyneuropathies
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Protective Agents
- Anti-Ulcer Agents
- Antioxidants
- Central Nervous System Stimulants
- Radiation-Protective Agents
- Actovegin
Other Study ID Numbers
- AV-007-IM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Symptomatic Diabetic Peripheral Polyneuropathy
-
heba ahmed khalifaActive, not recruitingDiabetic Peripheral NeuropathyEgypt
-
Imperial College LondonActegy Ltd.Not yet recruitingDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Diabetic Polyneuropathy | Diabetic ComplicationUnited Kingdom
-
Ilko Ilac San. ve Tic. A.S.CompletedPeripheral (Sensorimotor) Diabetic Polyneuropathy
-
Eva PharmaMARC-CRORecruiting
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedDiabetic Patients With PolyneuropathyNetherlands
-
Eisai Inc.CompletedMild to Moderate Diabetic Sensorimotor PolyneuropathyUnited States
-
NormaTec Industries LPNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)UnknownDiabetic PolyneuropathyUnited States
-
Instituto Mexicano del Seguro SocialInstituto Nacional de Salud Publica, Mexico; Universidad Nacional Autonoma... and other collaboratorsRecruitingEffect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy (EA&DPN)Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathy | Acupuncture | Diabetic Polyneuropathy | Electroacupuncture | Nerve ConductionMexico
-
Tanta UniversityCompletedDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Painful Diabetic Neuropathy | Autonomic Neuropathy | Diabetic Polyneuropathy | Small Fiber NeuropathyEgypt
-
SK Life Science, Inc.CompletedDiabetic Neuropathy, Painful | Diabetic Polyneuropathy | Diabetic Neuralgia | Diabetic Mononeuropathy
Clinical Trials on Deproteinised hemoderivative of calf blood (Actovegin)
-
Beijing Tiantan HospitalBeijing Stroke AssociationUnknownIntracerebral HemorrhageChina
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedPostural Tachycardia Syndrome (POTS)United States
-
The Cleveland ClinicRecruiting